Seroprevalence and risk factors of herpes simplex virus type-2 infection among pregnant women in northeast India
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*Background:* Herpes simplex virus type-2 (HSV-2) is one of the most common sexually transmitted infections that facilitate human immunodeficiency virus (HIV) acquisition by over two-fold or more. The development of HSV-2 control methods as a measure to control HIV epidemic in high HSV-2/HIV areas has become a priority. Two out of the six high HIV prevalent states of India are located in the northeastern region of India. Due to lack of documented HSV-2 studies from this part of the country; there was a need for estimating the seroprevalence and risk factors of HSV-2 infection in this defined population. *Methods:* Pregnant women (*n* = 1640) aged 18 years and above attending antenatal clinics of tertiary referral hospitals in five northeastern states of India were screened for type specific HSV-2 IgG antibodies. Blood samples were collected from all the participants after conducting interviews. Univariate and multivariate analyses were performed to identify the risk factors associated with HSV-2 seropositivity. *Results:* Overall seroprevalence of HSV-2 infection was 8.7% (142/1640; 95% CI: 7.3-10.0) with a highest prevalence of 15.0% (46/307; 95% CI: 11.0-19.0) in the state of Arunachal Pradesh. Higher seroprevalence was observed with increasing age (adjusted odds ratio \[AOR\]: 1.9 for 22-25 years old, AOR: 2.29 for \>29 years old). The risk factors associated with HSV-2 seropositivity were multiple sex partners (AOR: 2.5, *P* = 0.04), condom nonuser\'s (AOR: 4.7, *P* \< 0.001), early coitarchal age (age of first intercourse) "\<18 years" (AOR: 9.6, *P* = 0.04), middle income group (AOR: 2.1, *P* = 0.001) compared to low income group and low level of education (AOR: 3.7, *P* = 0.02) compared to higher education. HSV-2 seropositivity was higher among Christians (12.6%) compared to Muslims (3.8%). The most frequent clinical symptoms among HSV-2 seropositives were excess vaginal discharge in last 1 year (53.5%, 76/142) and pelvic pain (26.1%, 37/142). While among subjects with genital ulcers, HSV-2 seroprevalence was 36.8% (7/19). *Conclusions:* Overall seroprevalence of HSV-2 infection among pregnant women of Northeast India is relatively low. The generation of awareness among high risk groups may have played key role to limit the infection. The role of vaccination against HSV-2 in near future and elimination of HSV-2 viral shedding along with genital tract inflammation in high HIV/HSV-2 areas may be an option for initiating successful intervention strategies to reduce the transmission and acquisition of HIV infection in Northeast India.

Herpes simplex virus type 2: Seroprevalence in antenatal women
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*Aims:* The aim of the following study is to determine the seroprevalence of herpes simplex type 2 (HSV-2) infection in pregnant females, assess the frequency of unrecognized infection and identify the demographic profile and risk factors associated with the seroprevalence. *Materials and Methods:* A sample of 200 randomly selected, asymptomatic pregnant females attending the obstetrics and gynecology outpatient department for a routine antenatal checkup constituted the study group. Serum specimens were screened for HSV-2 infection by detecting IgG class antibodies against HSV-2-specific glycoprotein G-2 using an enzyme-linked immunosorbent assay kit. *Results:* A seroprevalence of 7.5% was found in our study. Seropositivity was maximum in the age group ≥30 years (22.20%), followed by 26-30 years (9.7%), 21-25 years (2.20%) and ≤20 years (0%). HSV-2 seropositivity was found to be significantly associated with increasing age, parity, number of sexual partners, duration of sexual activity and history of abortions (*P* \< 0.05). No statistically significant correlation was observed between seropositivity and other demographic variables such as place of residence, education, annual family income, and occupation (*P* \> 0.05). No statistically significant association of seropositivity with present or past history suggestive of other sexually transmitted infections was found. None of our cases tested positive for human immunodeficiency syndrome (HIV). *Conclusion:* A relatively low prevalence of HSV-2 seropositivity was found in our study, with a high frequency of unrecognized and asymptomatic infections. Our findings suggest that type-specific serotesting could be an efficient strategy to diagnose clinically asymptomatic HSV-2 infections and therefore, to reduce the risk of HSV-2 and HIV sexual transmission by prophylactic counseling against unprotected intercourse. It may also be a useful adjunct in detecting cases who present with symptoms not directly suggestive of genital herpes.
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Neonatal herpes simplex virus-2 (HSV) is most commonly transmitted at the time of delivery with the risk being dramatically higher if the mother has first-episode genital HSV and does not have an elective cesarean section. Maternal HSV type-specific serology can be used to differentiate first-episode from recurrent infection in this setting, allowing for use of empiric acyclovir for the highest risk infants. There is a need for new strategies as current methods of prevention of transmission of HSV to neonates have limited effectiveness, as they do not account for the fact that the majority of transmission occurs from asymptomatic women. After transmission has occurred, early recognition of neonatal HSV improves the prognosis. Diagnosis needs to be considered in all infants who develop vesicles, unexplained seizures, or possible sepsis in the first 5 weeks of life. Effects of valacyclovir on markers of disease progression in postpartum women co-infected with human immunodeficiency virus-1 and herpes simplex virus-2.
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*Objective:* Herpes simplex virus type 2 (HSV-2) suppression has been shown to reduce human immunodeficiency virus (HIV)-1 disease progression in nonpregnant women and men, but effects on pregnant and postpartum women have not been described. *Methods:* We analyzed data from a cohort of Kenyan women participating in a randomized clinical trial of HSV-2 suppression. Pregnant HIV-1-seropositive, HSV-2-seropositive women who were not eligible for antiretroviral therapy (WHO stage 1-2, CD4 \>250 cells/μl) were randomized to either 500 mg valacyclovir or placebo twice daily from 34 weeks gestation through 12 months postpartum. Women received zidovudine and single-dose nevirapine for prevention of mother-to-child HIV-1 transmission. HIV-1 progression markers, including CD4 count and plasma HIV-1 ribonucleic acid (RNA) levels, were measured serially. Multivariate linear regression was used to compare progression markers between study arms. *Results:* Of 148 women randomized 136 (92%) completed 12 months of postpartum follow-up. While adjusted mean CD4 count at 12 months (565 cells/μl placebo arm, 638 cells/μl valacyclovir arm) increased from antenatal levels in both arms, the mean CD4 count increase was 73 cells/μl higher in the valacyclovir arm than placebo arm (*P* = 0.03). Mean increase in CD4 count was 154 cells/μl in the valacyclovir arm, almost double the increase of 78 cells/μl in the placebo arm. At 12 months, adjusted HIV-1 RNA levels in the placebo arm increased by 0.66 log (10) copies/ml from baseline, and increased by only 0.21 log (10) copies/ml in the valacyclovir arm (0.40 log (10) copies/ml difference, *P* = 0.001). *Conclusion:* Women randomized to valacyclovir suppressive therapy during pregnancy and postpartum had greater increases in CD4 counts and smaller increases in plasma HIV-1 RNA levels than women in the placebo arm. Valacyclovir suppression during pregnancy and breastfeeding may improve outcomes and delay antiretroviral therapy for HIV-1/HSV-2 co-infected women.

Acyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: An open-label trial
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*Objective:* To continue evaluation of the use of acyclovir suppression in late pregnancy after first episode genital herpes simplex virus (HSV) infection, using an open-label study design. *Methods:* Ninety-six women diagnosed with genital herpes for the first time in the index pregnancy were prescribed suppressive acyclovir 400 mg orally 3 times daily from 36 weeks until delivery in an open-label fashion. Herpes cultures were obtained when patients presented for delivery. Vaginal delivery was permitted if no clinical recurrence was present; otherwise a cesarean delivery was performed. Neonatal HSV cultures were obtained and infants were followed clinically. Rates of clinical and asymptomatic genital herpes recurrences and cesarean delivery for genital herpes were measured, and 95% confidence intervals were calculated. *Results:* In 82 patients (85%) compliant with therapy, only 1% had clinical HSV recurrences at delivery. In intent to treat analysis of the entire cohort, 4% had clinical recurrences (compared with 18-37% in historical controls). Asymptomatic shedding occurred in 1% of women without lesions at delivery. Two of the four clinical recurrences were HSV-culture positive. No significant maternal or fetal side-effects were observed. *Conclusions:* In clinical practice, the majority of patients are compliant with acyclovir suppression at term. The therapy appears to be effective at reducing clinical recurrences after a first episode of genital herpes complicating a pregnancy.
